Evaxion Biotech AS (EVAX)
4.04
+0.16
(+4.12%)
USD |
NASDAQ |
May 24, 13:31
Evaxion Biotech Enterprise Value: 23.30M for May 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 23, 2024 | 23.30M |
| May 22, 2024 | 22.93M |
| May 21, 2024 | 21.68M |
| May 20, 2024 | 22.47M |
| May 17, 2024 | 22.47M |
| May 16, 2024 | 23.04M |
| May 15, 2024 | 23.25M |
| May 14, 2024 | 22.47M |
| May 13, 2024 | 22.73M |
| May 10, 2024 | 22.47M |
| May 09, 2024 | 22.73M |
| May 08, 2024 | 23.25M |
| May 07, 2024 | 23.46M |
| May 06, 2024 | 23.46M |
| May 03, 2024 | 23.66M |
| May 02, 2024 | 23.35M |
| May 01, 2024 | 23.46M |
| April 30, 2024 | 24.81M |
| April 29, 2024 | 25.44M |
| April 26, 2024 | 24.86M |
| April 25, 2024 | 24.55M |
| April 24, 2024 | 24.60M |
| April 23, 2024 | 24.66M |
| April 22, 2024 | 24.92M |
| April 19, 2024 | 25.54M |
| Date | Value |
|---|---|
| April 18, 2024 | 25.07M |
| April 17, 2024 | 24.50M |
| April 16, 2024 | 24.13M |
| April 15, 2024 | 24.45M |
| April 12, 2024 | 24.45M |
| April 11, 2024 | 23.35M |
| April 10, 2024 | 23.87M |
| April 09, 2024 | 23.72M |
| April 08, 2024 | 24.39M |
| April 05, 2024 | 22.31M |
| April 04, 2024 | 22.10M |
| April 03, 2024 | 21.84M |
| April 02, 2024 | 23.30M |
| April 01, 2024 | 19.91M |
| March 28, 2024 | 19.75M |
| March 27, 2024 | 18.71M |
| March 26, 2024 | 19.39M |
| March 25, 2024 | 19.23M |
| March 22, 2024 | 18.97M |
| March 21, 2024 | 18.97M |
| March 20, 2024 | 18.87M |
| March 19, 2024 | 19.08M |
| March 18, 2024 | 19.13M |
| March 15, 2024 | 18.66M |
| March 14, 2024 | 17.26M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
13.65M
Minimum
Jun 17 2022
232.76M
Maximum
Nov 04 2021
54.72M
Average
35.60M
Median
Mar 02 2022
Enterprise Value Benchmarks
| DBV Technologies SA | 16.71M |
| Ascendis Pharma A/S | 7.769B |
| Cellectis SA | 38.45M |
| Adaptimmune Therapeutics PLC | 114.47M |
| Akari Therapeutics PLC | 13.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.523M |
| Revenue (Quarterly) | 0.073M |
| Total Expenses (Quarterly) | 4.437M |
| EPS Diluted (Quarterly) | -1.50 |
| Profit Margin (Quarterly) | -6.20K% |
| Earnings Yield | -200.5% |